This information would in turn guide us in the identification of suitable RET inhibitors and their appropriate delivery protocols for long-term in vivo testing in ALS animal models, both at pre-symptomatic and early symptomatic stages of disease progression. The gene discussed is RET; the disease is amyotrophic lateral sclerosis.